ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 60 citations in OpenAlex.
- Bioprinted Bladder Cancer Organoids Model System for Prediction of Chemotherapy Response and Drug Screening.International journal of molecular sciences · 2026Article
- Synergistic effects through targeting the PI3K and IGFR pathways in treating lung cancer carrying activation alterations along the PI3K pathway.Translational oncology · 2026Article
- Pioglitazone Mitigates Arsenic-Induced Cardiotoxicity via Lipid Metabolism: Network Pharmacology and Molecular Docking Approach.Cardiovascular toxicology · 2026Article
- scXDR: drug response prediction across single-cell datasets via heterogeneous network transfer learning.Communications biology · 2026Article
- Pulsed Electromagnetic Field Therapy Alters the Genomic Profile of Bladder Cancer Cell Line HT-1197.Journal of personalized medicine · 2025Article
- Leukocyte-specific protein 1 is associated with the stage and tumor immune infiltration of cervical cancer.Scientific reports · 2025Article
- Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell lines.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Predictive Molecular Biomarkers of Bladder Cancer Identified by Next-Generation Sequencing-Preliminary Data.Journal of clinical medicine · 2024Article
- Comprehensive Collection of Whole-Slide Images and Genomic Profiles for Patients with Bladder Cancer.Scientific data · 2024Article
- Landscape of targeted therapies for advanced urothelial carcinoma.Exploration of targeted anti-tumor therapy · 2024Review
- GREM1 is a potential biomarker for the progression and prognosis of bladder cancer.World journal of surgical oncology · 2023Article
- Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.Journal of personalized medicine · 2023Review
- Sea Cucumber Derived Triterpenoid Glycoside Frondoside A: A Potential Anti-Bladder Cancer Drug.Nutrients · 2023Article
- Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges.Journal of nanobiotechnology · 2022Review
- ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors.JCI insight · 2022Article
- Lymphocyte-Specific Protein-1 Suppresses Xenobiotic-Induced Constitutive Androstane Receptor and Subsequent Yes-Associated Protein-Activated Hepatocyte Proliferation.The American journal of pathology · 2022Article
- Gypenoside-Induced Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in Bladder Cancer.BioMed research international · 2022Article
- Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment.Frontiers in oncology · 2022Article
- Development and Validation of Ferroptosis-Related LncRNA Biomarker in Bladder Carcinoma.Frontiers in cell and developmental biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 2 countries.
Shu-Xiong ZengDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, California.
Yanjun ZhuDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, California.
Ai-Hong MaDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, California.
Weimin YuDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, California.
Hongyong ZhangDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, California.
Tzu-Yin LinDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, California.
Wei ShiDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, California.
Clifford G TepperDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, California.
Paul T HendersonDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, California.
Susan AirhartThe Jackson Laboratory, Bar Harbor, Maine.
Jian-Ming GuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chuan-Liang XuDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China. cxpan@ucdavis.edu xuchuanliang@vip.126.com.
Ralph W deVere WhiteDepartment of Urology, University of California Davis Comprehensive Cancer Center, Sacramento, California.
Chong-Xian PanDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, California. cxpan@ucdavis.edu xuchuanliang@vip.126.com.
University of California, Davis · USFudan University · CNSecond Military Medical University · CNJackson Laboratory · USUniversity of California Davis Medical Center · USVA Northern California Health Care System · USWuhan University · CNXijing Hospital · CN
Funding
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9MDevelopment of targeting nanotherapeutics against bladder cancerI01BX001784 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI PAN, CHONG-XIAN · 2014 to 2017
–BLRD VA I01 BX001784NCI NIH HHS P30 CA093373
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsCell Line, TumorCisplatinClass I Phosphatidylinositol 3-KinasesDeoxycytidineDrug Resistance, NeoplasmGemcitabineGene Expression Regulation, NeoplasticHumansIndazolesMiceMutationPhosphatidylinositol 3-KinaseProtein Kinase InhibitorsSignal TransductionSulfonamides2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidineCisplatinClass I Phosphatidylinositol 3-KinasesDeoxycytidineGemcitabineIndazolesPhosphatidylinositol 3-KinasePIK3CA protein, humanProtein Kinase InhibitorsSulfonamides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.